Stockscreener 앱 받기
0.17
37.06%
-0.1001
전일 마감가:
$0.2701
열려 있는:
$0.25
하루 거래량:
33.50M
Relative Volume:
19.89
시가총액:
$9.47M
수익:
-
순이익/손실:
$-31.39M
주가수익비율:
-0.2024
EPS:
-0.84
순현금흐름:
$-18.45M
1주 성능:
-94.48%
1개월 성능:
-94.79%
6개월 성능:
-89.70%
1년 성능:
-89.38%
1일 변동 폭
$0.161
$0.2575
1주일 범위
$0.161
$3.4102
52주 변동 폭
$0.161
$4.5499
Quince Therapeutics Inc Stock (QNCX) Company Profile
명칭
Quince Therapeutics Inc
전화
415-910-5717
주소
611 GATEWAY BLVD., SUITE 273, SOUTH SAN FRANCISCO
QNCX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
QNCX
Quince Therapeutics Inc
|
0.17 | 15.04M | 0 | -31.39M | -18.45M | -0.84 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.90 | 120.69B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.45 | 78.77B | 14.34B | 4.50B | 3.88B | 41.57 |
|
ARGX
Argen X Se Adr
|
840.50 | 52.46B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
338.06 | 45.82B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
340.38 | 38.73B | 4.98B | 69.59M | 525.67M | 0.5197 |
Quince Therapeutics Inc Stock (QNCX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-08-05 | 개시 | Citizens JMP | Mkt Outperform |
| 2025-03-24 | 개시 | Oppenheimer | Outperform |
Quince Therapeutics Inc 주식(QNCX)의 최신 뉴스
Lucid Cap Mkts Downgrades Quince Therapeutics (NASDAQ:QNCX) to Strong Sell - Defense World
Quince Therapeutics (NASDAQ:QNCX) Cut to Hold at Brookline Capital Management - Defense World
Quince’s eDSP on ice after Neat phase III fails in A-T - BioWorld MedTech
Quince Therapeutics’ Fruit Spoils As Phase III A-T Study Falls To Ground - Citeline News & Insights
This Codere Online Luxembourg Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Friday - Benzinga
Quince Therapeutics (QNCX) Downgraded by Citizens to Market Perf - GuruFocus
Quince Therapeutics stock rating downgraded to Hold by D. Boral Capital By Investing.com - Investing.com Nigeria
Quince Therapeutics stock rating downgraded to Hold by D. Boral Capital - Investing.com Canada
QNCX Downgraded to 'Hold' by D. Boral Capital Analyst | QNCX Sto - GuruFocus
Lucid Capital Markets downgrades Quince Therapeutics stock to Sell after failed trial - Investing.com
Quince Therapeutics Stock Collapses After Key Trial Update In Rare Genetic Disease - Benzinga
Quince Therapeutics (NASDAQ:QNCX) Cut to Market Perform at Citizens Jmp - MarketBeat
Quince Therapeutics (QNCX) Downgraded Following Phase 3 Trial Mi - GuruFocus
Quince Therapeutics’ (QNCX) “Buy” Rating Reaffirmed at D. Boral Capital - Defense World
Quince Therapeutics stock rating downgraded by Citizens after Phase 3 trial failure - Investing.com
Quince Therapeutics phase 3 trial for rare disease fails to meet endpoints By Investing.com - Investing.com South Africa
Why Did QNCX Stock Plummet Over 90% Today? - Asianet Newsable
Quince Therapeutics Announces Results from Phase 3 NEAT Trial - TradingView
QNCX Stock Plummets 88% After Ceasing eDSP Development - GuruFocus
QNCX Strategizes to Conserve Resources and Evaluate Opportunitie - GuruFocus
Quince Therapeutics phase 3 trial for rare disease fails to meet endpoints - Investing.com Canada
Quince Therapeutics Halts Development of Neurological Drug Candidate; Shares Plunge - marketscreener.com
Quince Therapeutics drops after co's drug fails to meet main goal in late-stage trial - TradingView
Quince Therapeutics (QNCX) Faces Setback with Phase 3 Trial Resu - GuruFocus
Quince Therapeutics stock tumbles after failed Phase 3 trial results - Investing.com
Quince Therapeutics Announces Topline Results from Pivotal Phase 3 NEAT Clinical Trial of eDSP in Ataxia-Telangiectasia - Business Wire
Is Quince Therapeutics Inc. stock showing strong momentumFed Meeting & Free Fast Entry Momentum Trade Alerts - mfd.ru
Quince Therapeutics (NASDAQ:QNCX) Given "Buy" Rating at D. Boral Capital - MarketBeat
QNCX: D. Boral Capital Maintains Buy Rating and Price Target | Q - GuruFocus
Quince Therapeutics Presents Safety Data from Long-Term eDSP Treatment in Children with Ataxia-Telangiectasia at British Paediatric Neurology Association Annual Meeting - BioSpace
Quince's Clinical Trial Fails to Meet Key Endpoints - Intellectia AI
Quince Therapeutics (QNCX) Highlights Safety of Long-Term Treatm - GuruFocus
Ideas Watch: Is Quince Therapeutics Inc stock showing strong momentumProduct Launch & AI Based Buy and Sell Signals - baoquankhu1.vn
Citizens reiterates Market Outperform rating on Quince Therapeutics stock - Investing.com
Is Quince Therapeutics (NASDAQ:QNCX) Using Debt Sensibly? - simplywall.st
Investor Mood: Can Synergy CHC Corp weather a recessionStop Loss & Precise Buy Zone Identification - baoquankhu1.vn
Quince Therapeutics, Inc. (NASDAQ:QNCX) Sees Significant Growth in Short Interest - MarketBeat
Weekly Recap: Can Quince Therapeutics Inc sustain its profitabilityJuly 2025 Price Swings & Low Risk High Reward Trade Ideas - baoquankhu1.vn
Stock Traders Buy Large Volume of Quince Therapeutics Call Options (NASDAQ:QNCX) - MarketBeat
QNCX Sees Increased Price Target Amidst Maintained Buy Rating | - GuruFocus
Panic Selling: Will Quince Therapeutics Inc stock deliver strong dividend growth2025 Market WrapUp & Verified High Yield Trade Plans - Bộ Nội Vụ
Levels Update: Is Quince Therapeutics Inc stock showing strong momentumQuarterly Profit Report & Weekly High Potential Stock Alerts - baoquankhu1.vn
Volume Summary: Why Quince Therapeutics Inc stock appeals to analystsMarket Performance Report & Low Risk Entry Point Guides - Bộ Nội Vụ
Quince Therapeutics: Good Potential In Orphan Disease In Q1 With Platform Potential - Seeking Alpha
Quince Therapeutics, Inc. (NASDAQ:QNCX) Receives Consensus Rating of “Moderate Buy” from Brokerages - Defense World
Can Quince Therapeutics Inc. stock beat market expectations this quarterFit and Size Notes & lightweight options for faster days - Улправда
Citizens reiterates Market Outperform rating on Quince Therapeutics stock By Investing.com - Investing.com Nigeria
Can Quince Therapeutics Inc. stock sustain institutional interestJuly 2025 Rallies & Daily Volume Surge Signals - Улправда
Returns Recap: How Quince Therapeutics Inc. stock compares to industry benchmarksTrade Risk Assessment & Risk Managed Investment Entry Signals - Улправда
Will Quince Therapeutics Inc. stock outperform value stocksPortfolio Risk Assessment & Minimal Capital Trading Tips - Улправда
Quince Therapeutics reports Q3 EPS (25c), consensus (22c) - MSN
Quince Therapeutics Inc (QNCX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Quince Therapeutics Inc 주식 (QNCX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Benatti Luca | Director |
Dec 26 '25 |
Sale |
3.47 |
50,000 |
173,500 |
39,179 |
| Hannah Brendan | CBO, COO & CCO |
Dec 05 '25 |
Option Exercise |
0.91 |
27,551 |
25,012 |
361,827 |
1.27%
자본화:
|
볼륨(24시간):